Qualitative detection of new coronavirus (SARS-CoV-2) IgM antibodies in human serum or plasma using enzyme-linked immunoassay technology, which can better complement the nucleic acid detection methodology and provide a more comprehensive reference for clinical diagnosis.
IgM appears firstly after the virus infection and IgG occurs a few days later. SARS-CoV-2 specifie IgM antibody usually appears positive 3-5 days since infection. The titer of IgG in recovery phase is 4 times higher than that in acuter phase.
Testing IgM/lgG antibodies can auxiliary diagnose whether the patient has recently been infected with SARS-CoV-2 Virus.
Diagnostic Kit for SARS-CoV-2 IgM Antibody
The Dignostic Kit for SARS-CoV-2 IgM Antibody (ELISA) from KHB adopts the capture immunoassay for the qualitative détermination of IgM antibody to SARS-CoV-2 in human sérum and plasma.
-Product Features
Application: the test kit is an enzyme immunoassay for the in vitro qualitative determination of IgM or IgG antibody for SARS-CoV-2.
Specimens: human serum and plasma ;High Throughput: 96 tests/microplate, the result can be automatically read.
Cost Effective: simple operation, simple equipment requirements
Safety: no radioactive pollution
Storage: store at 2-8°C environment and protected from light,shelf-life is 6 months.